ASPREE and Cancer

The ASPREE clinical trial commenced in 2010 and finished in 2017, was a multi-centre clinical trial looking at whether low dose aspirin could prolong life free of mental and physical disability. The intervention phase of the trial has now concluded, but these participants are now being followed for a further five years through the ASPREE extension study (ASPREE-XT), which is a longitudinal observation study. Data is collected form participants twice a year, via an in-person visit annually and a phone call follow up 6 months later. ASPREE and -XT capture a wealth of phenotypic data from its participants, including the major health related events linked to ageing (cognitive decline, physical decline and frailty, cancer, depression and cardio/cerebrovascular disease). My area of interest is cancer, and I would be interested in supporting any research that utilises the ASPREE/-XT cancer related data. ASPREE/-XT also collects biospecimens from its participants (blood/urine and tumour tissue samples) to provide a DNA biobank of both somatic and tumour tissue DNA. from it's participants . Cancer related projects can include investigating associations between cancer and other chronic diseases, risk factors, and screening.